De novo designed protein 4H_01 in complex with Mota antibody
External Resource: Annotation
| Chains | Family Name | Domain Identifier | Architecture | Possible Homology | Homology | Topology | Family | Provenance Source (Version) |
|---|
| A | PF07654 | e6ywdA1 | A: beta sandwiches | X: Immunoglobulin-like beta-sandwich | H: Immunoglobulin-related | T: Immunoglobulin/Fibronectin type III/E set domains/PapD-like | F: PF07654 | ECOD (1.6) |
| A | PF07686 | e6ywdA2 | A: beta sandwiches | X: Immunoglobulin-like beta-sandwich | H: Immunoglobulin-related | T: Immunoglobulin/Fibronectin type III/E set domains/PapD-like | F: PF07686 | ECOD (1.6) |
| B | PF07654 | e6ywdB1 | A: beta sandwiches | X: Immunoglobulin-like beta-sandwich | H: Immunoglobulin-related | T: Immunoglobulin/Fibronectin type III/E set domains/PapD-like | F: PF07654 | ECOD (1.6) |
| B | PF07686 | e6ywdB2 | A: beta sandwiches | X: Immunoglobulin-like beta-sandwich | H: Immunoglobulin-related | T: Immunoglobulin/Fibronectin type III/E set domains/PapD-like | F: PF07686 | ECOD (1.6) |
| Chain | Protein Name | Description | Organism Name | Gene Allele Name(s) | Domain Name(s) | Receptor Type | Receptor Description | Provenance Source |
|---|
| | human | VH-CH1 | Homo sapiens (human) | IGHV2-70*19, IGHJ6*01, IGHG1*01, IGHG1*02, IGHG1*04, IGHG1*05, IGHG1*12, IGHG1*14, IGHG1*13, IGHG1*09, IGHG1*10, IGHG1*07, IGHG1*11 | V-DOMAIN VH, C-DOMAIN CH1 | IG | FAB-GAMMA-1_KAPPA | IMGT (202416-0) |
| | human | L-KAPPA | Homo sapiens (human) | IGKV1-5*01, IGKJ4*01, IGKJ4*02, IGKC*01 | V-DOMAIN V-KAPPA, C-DOMAIN C-KAPPA | IG | FAB-GAMMA-1_KAPPA | IMGT (202416-0) |
| Chain | Chain Class | Chain Subclass | Chain Type | Antigen Name(s) | Provenance Source |
|---|
| | Heavy Chain | IGHV2 | - | de novo designed protein 4h_01 | SAbDab (2024-04-26) |
| | Light Chain | IGKV1 | Kappa | de novo designed protein 4h_01 | SAbDab (2024-04-26) |
| Chain | Name | Target | Provenance Source |
|---|
| Motavizumab | Respiratory Syncytial Virus Glycoprotein F | Therapeutic SAbDab (2024-04-26) |
| Motavizumab | Respiratory Syncytial Virus Glycoprotein F | Therapeutic SAbDab (2024-04-26) |
